What's the outlook for ARAY's EPS in late 2025?

The outlook for Accuray's (ARAY) EPS in late 2025 appears challenging based on the available data and market analysis. Here's a detailed assessment:

1. **Current Financial Projections**: The estimates for ARAY's EPS in late 2025 (September 30, 2025) are -$0.05, -$0.04, and -$0.01 for the three months ending respectively. This indicates a potential for negative earnings in the period.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|ARAY|ARAY.O|Accuray|2025 Q1|-33.33333333333334|-0.04|185|
|ARAY|ARAY.O|Accuray|2025 Q2|120|0.02|185|

2. **Recent Performance and Challenges**: Accuray has faced a decline of 46.3% year-to-date compared to the industry's 4.8% growth, which suggests significant headwinds. The company's net loss for the fiscal year 2023 was $15.5 million, with a net loss per share of $(0.16), reflecting financial strain.
3. **Market Optimism and Potential Growth Areas**: Despite the challenges, there are positive indicators for growth. Accuray's CyberKnife System has seen a significant revenue growth of over 50% year-over-year, driven by strong global demand and performance in the second quarter of fiscal 2025. The company's Precision Treatment Planning System (TPS) has also received approval in China, which could open up new markets and contribute to future growth.
4. **Strategic Positioning and Future Prospects**: Accuray's strategic partnerships and direct sales presence in key regions suggest a proactive approach to market expansion. The company's focus on innovative radiation therapy solutions and technological advancements, such as AI-driven radiology, position it well for long-term growth.

In conclusion, while there are positive signs of growth and innovation, the immediate outlook for ARAY's EPS in late 2025 is likely to be impacted by the current financial projections and recent performance. The company's ability to execute on growth initiatives and manage challenges will be critical in determining the final EPS figures for the period.